Steatosis News and Research

RSS

New molecule could help fight type 2 diabetes and non-alcoholic fatty liver disease

A new molecule -EPB-53-, could help fight type 2 diabetes and the non-alcoholic fatty liver disease, according to a new study led by the team of Manuel Vázquez-Carrera, from the Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine of the University of Barcelona, and the Diabetes and Associated Metabolic Diseases Networking Biomedical Research Center.

10 Apr 2019

Study elucidates mechanism behind development of steroid diabetes

Steroids are used for treating various diseases such as allergic disorders, but they occasionally cause adverse effects, such as steroid diabetes and other metabolic disturbances. Since steroids act throughout the body, how these adverse effects are caused and by which organ are not well understood.

28 Feb 2019

Study examines relationship between growth restriction and risk of childhood mortality

Almost all children live to see their eighteenth birthday despite a severe growth restriction, as long as they have survived their first month during infancy. This is indicated in a study by researchers at Karolinska Institutet, which is published in the journal PLOS Medicine.

18 Dec 2018

Green leafy vegetables may reduce risk of developing liver steatosis

A larger portion of green leafy vegetables in the diet may reduce the risk of developing liver steatosis, or fatty liver. In a study published in PNAS researchers from Karolinska Institutet in Sweden show how a larger intake of inorganic nitrate, which occurs naturally in many types of vegetable, reduces accumulation of fat in the liver.

17 Dec 2018

New project aims to estimate scientific basis of health risks posed by substance mixtures

The BfR is involved with two work groups in the project, which is being coordinated by the Dutch National Institute for Public Health and the Environment

1 Nov 2018

Novartis enters into clinical development agreement with Pfizer to improve treatment of NASH

Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).

29 Oct 2018

Researchers identify new potential target to inhibit progression of liver disease

Naglaa Shoukry, Ph. D., and her team have made a significant breakthrough in their research aiming to limit the progression of liver disease.

26 Oct 2018

Mast cells associated with allergies also play key role in survival, study reveals

In a University of California, Irvine-led study, researchers found evidence that mast cells, an important group of immune cells typically associated with allergies, actually enable the body to survive fasting or intense exercise.

12 Oct 2018

Scientists find new way to predict obesity-related disease risk

Scientists at Scripps Research and collaborating corporate and academic partners have found a new way to use distinct molecular "signatures" from people with obesity to predict risk of developing diabetes and cardiovascular disease, an advance that could broaden the way doctors and scientists think about diagnosing and treating disease.

12 Oct 2018

Losing a single night's sleep may increase risk of metabolic diseases

Losing a single night's sleep may affect the liver's ability to produce glucose and process insulin, increasing the risk of metabolic diseases such as hepatic steatosis (fatty liver) and type 2 diabetes.

5 Sep 2018

Researchers use gene therapy to cure obesity and type 2 diabetes in mice

A research team from the UAB led by Professor Fatima Bosch has managed to cure obesity and type 2 diabetes in mice using gene therapy.

9 Jul 2018

Naturally occurring antibody can block inflammation in mice, finds study

Researchers at University of California San Diego School of Medicine discovered that they can block inflammation in mice with a naturally occurring antibody that binds oxidized phospholipids, molecules on cell surfaces that get modified by inflammation.

7 Jun 2018

Key metabolites shed by gut bacteria can help protect from inflammation, study finds

Researchers at Tufts University have elucidated a mechanism by which the "good" bacteria that reside in our gastrointestinal tract can help protect us from inflammation, and how their disruption (dysbiosis) can increase the susceptibility of the liver to more harmful forms of disease.

4 May 2018

Lipodystrophy: The Importance of Awareness

An interview with Rebecca Sanders, Lipodystrophy UK co-founder, discussing the importance of awareness campaigns for patients and society at large.

3 Apr 2018

Gastrointestinal hormone offers possible new treatment for NAFLD and NASH patients

Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers at University of California San Diego School of Medicine report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

9 Mar 2018

Fat hormone associated with NASH may be effective target for therapeutic intervention

The rising obesity epidemic has brought with it an army of maladies. One, in particular, is threatening to outpace many of the disorders that accompany obesity, in terms of occurrence and severity: nonalcoholic fatty liver disease.

7 Nov 2017

Common acid reflux drugs linked to progression of chronic liver disease

Approximately 10 percent of the general population take a proton pump inhibitor (PPI) drug to block stomach acid secretions and relieve symptoms of frequent heartburn, acid reflux and gastroesophageal reflux disease.

10 Oct 2017

Diet plus alcohol may play key role in liver injury development

A new study published in Alcohol and Alcoholism finds that mice bred to consume high amounts of alcohol, but controlled by diet, did not necessarily develop the most severe liver injuries, suggesting that diet may pay an important role in liver injury development.

25 Sep 2017

Researchers find signaling pathway in cells that plays key role in development of fatty liver disease

Morbid obesity affects the liver: Almost one-third of all adults suffer from chronic fatty liver disease, which can lead to infections and even trigger cancer. Researchers at the University Children's Hospital Zurich and the University of Zurich have now found a signaling pathway in cells that play an important role in the development of fatty liver disease.

7 Sep 2017

Unfolded protein response could be cause of metabolic disorders, say researchers

The cell's response to unfolded or misfolded proteins could be a cause, rather than a consequence, of metabolic disorders, report researchers at the Medical University of South Carolina in an article published online ahead of print on September 4, 2017 by Nature Structural & Molecular Biology.

4 Sep 2017